HC Wainwright & Co. Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $13
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and announces Price Target of $13.
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and announces Price Target of $13.